Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease | Zendy

Jessica L. Mega | Zendy; Willibald Hochholzer | Zendy; Andrew L. Frelinger | Zendy; Michael Kluk | Zendy; Dominick J. Angiolillo | Zendy; Larry S. Dean | Zendy; Steven Isserman | Zendy; William J. Rogers | Zendy; Christian T. Ruff | Zendy; Charles F. Contant | Zendy; Michael Pencina | Zendy; Benjamin M. Scirica | Zendy; Janina A. Longtine | Zendy; Alan D. Michelson | Zendy; Marc S. Sabatine | Zendy

Open Access

Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease

Author(s) -

Jessica L. Mega,

Willibald Hochholzer,

Andrew L. Frelinger,

Michael Kluk,

Dominick J. Angiolillo,

Larry S. Dean,

Steven Isserman,

William J. Rogers,

Christian T. Ruff,

Charles F. Contant,

Michael Pencina,

Benjamin M. Scirica,

Janina A. Longtine,

Alan D. Michelson,

Marc S. Sabatine

Publication year - 2011

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2011.1703

Subject(s) - medicine , clopidogrel , cyp2c19 , context (archaeology) , ticlopidine , gastroenterology , cardiology , aspirin , paleontology , cytochrome p450 , metabolism , biology

Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research